secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001193125-23-138257
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Q1 net loss $35.5M ($0.43/share); cash $620.5M; progresses bemnifosbuvir trials
--------------------------------------------------------------------------------

- Net loss of $35.5M ($0.43 diluted EPS) vs $42.1M ($0.51) in Q1 2022; no revenue.
- Cash, cash equivalents & marketable securities $620.5M at March 31, 2023 vs $646.7M at Dec 31, 2022.
- R&D expense $29.0M, G&A $12.6M; both roughly flat YoY; interest income rose to $6.3M.
- FDA granted Fast Track designation for bemnifosbuvir in COVID-19; Phase 3 SUNRISE-3 enrolling.
- Phase 2 HCV combination (bemnifosbuvir + ruzasvir) dosing expected 2Q23; initial data 4Q23; dengue program deprioritized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312523138257/0001193125-23-138257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312523138257/d391656d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-138257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer